Phase i clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC)

Pharmazie

Volumn 67, Issue 3, 2012, Pages 233-241

  Bittner, Beate ^a   McIntyre, C ^a   Tian, H ^b   Tang, K ^b   Shah, N ^b   Phuapradit, W ^b   Ahmed, H ^b   Chokshi, H ^b   Infeld, M ^b   Fotaki, N ^c   Ma, H ^b   Portron, A ^a   Jordan, P ^a   Schmidt, J ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HOFFMANN LA ROCHE INC   (United States)

^c University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXCIPIENT; IBANDRONIC ACID; SODIUM N [8 (2 HYDROXYBENZOYL) AMINO] CAPRYLATE; UNCLASSIFIED DRUG; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; N (8 (2 HYDROXYBENZOYL)AMINO)CAPRYLATE; N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLATE; OCTANOIC ACID DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BACKACHE; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; ADULT; ALGORITHM; ANALYSIS OF VARIANCE; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DELIVERY SYSTEM; HALF LIFE TIME; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SOLUBILITY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALGORITHMS; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BONE DENSITY CONSERVATION AGENTS; CAPRYLATES; CHEMISTRY, PHARMACEUTICAL; COHORT STUDIES; CROSS-OVER STUDIES; DIPHOSPHONATES; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; SOLUBILITY; YOUNG ADULT;

EID: 84861170949     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1648     Document Type: Article

References (16)

1. Barrett J, Worth E, Bauss F, Epstein S (2004) Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 44: 951-965.
2. Brayden D, Creed E, O'Connell A, Leipod H, Agarwal R, Leone-Bay A (1997) Heparin absorption across the intestine: effects of sodium N-[8-(2- hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in caco-2 monolayers. Pharm Res 14: 1772-1779.
3. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Min Res 19: 1241-1249.
4. Delmas P, Recker R, Stakkestad JA, Chestnut C III, Hoiseth A, Wiechelberger A, Huss H, von Stein T, Schimmer R (2002) Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: results from a pivotal phase III study. Osteoporos Int 13: S15.
5. Ding X, Rath P, Angelo R, Stringfellow T, Flanders E, Dinh S, Gomez-Orellana I, Robinson JR (2004) Oral absorption enhancement of cromolyn sodium through noncovalent complexation. Pharm Res 21: 2196-2206.
6. Leone-Bay A, Paton DR, Variano B, Leipold H, Rivera T, Miura-Fraboni J, Baughman RA, Santiago N (1998) Acylated non-alpha aminoacids a novel agents for the oral delivery of heparin sodium USP. J Control Release 50: 41-49.
7. Leone-Bay A, Sato M, Paton D, Hunt AH, Sarubbi D, Carozza M, Chou J, McDonough J, Baughman RA (2001) Oral delivery of biologically active parathyroid hormone. Pharm Res 18: 964-970.
8. Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18: 75-85.
9. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Min Res 20: 1315-1322.
10. Malkov D, Angelo R, Wang HZ, Flanders E, Wang H, Gomez OI (2005) Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv 2: 191-197.
11. Malkov D, Wang HZ, Dinh S, Gomez-Orellana I (2002) Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate. Pharm Res 19: 1180-1184.
12. Mitchell DY, Eusebio RA, Dunlap LE, Pallone KA, Nesbitt JD, Russell DA, Clay M, Bekker P (1998) Risedronate gastrointestinal absorption is independent of site and rate of administration. Pharm Res 15: 228-232.
13. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65: 654-661.
14. Song NN, Zhang SY, Liu CX (2004) Overview of factors affecting oral drug absorption. Asia J Drug Metab Pharmacokinet 4: 167-176.
15. Wu SJ, Robinson JR (1999a) Transport of human growth hormone across caco-2 cells with novel delivery agents: evidence for p-glycoprotein involvement. J Control Release 62: 171-177.
16. Wu SJ, Robinson JR (1999b) Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone. Pharm Res 16: 1266-1272.